Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Henry L Niman, PhD
Audios: Dec2 Dec17 Dec30 Jan6 Jan13 Jan16 Jan21
http://www.recombinomics.com/whats_new.html
Henry L Niman, PhD
AUDIO: Jan21
http://www.recombinomics.com/whats_new.html
NOTE: You might have to copy and past the link to access the audios.
BIRD FLU NEWS
Indonesian nurse with bird flu-like symptoms hospitalized
UPDATED: 11:28, June 03, 2006
A 25-year old nurse identified by her initials as "Ci" is currently being treated at the Hasan Sadikin Hospital for bird flu-like symptoms in Bandung, capital of West Java province, Indonesia.
Ci was admitted to the hospital which has been treating a number of bird flu patients on Thursday evening, Antara news agency reported on Friday.
"When she arrived at this hospital last night, her body temperature was very high, namely 39.6 Celsius degrees but now it has decreased to 37 Celsius degrees," Hadi Jusuf, head of the bird flu medical treatment unit of the hospital, was quoted as saying Friday.
The hospital was planning to send the patient's blood sample to the laboratory of the Health Development and Research Body in Jakarta.
"We could not confirm whether she is positive of having been infected by avian influenza virus or not, although she had earlier have contacts with siblings, 18-year old Ad and 10-year old Ai, who died of bird flu virus recently," he said.
The ailing nurse has never had contact with poultry, but she had treated the sibling when being treated at Ujungberung Hospital, where Ci works as a nurse.
If she is confirmed of being infected by bird flu virus, it would be the first case of human-to-human transmission of the virus, he said.
Meanwhile, the UN World Health Organization (WHO) recently announced that international health investigators were finding no evidence that efficient transmission of the highly pathogenic avian influenza virus has emerged from a family cluster of cases in Indonesia's North Sumatra.
The H5N1 virus has caused 127 deaths in 224 cases worldwide since it was detected in humans in late 2003. In all but a handful of cases, humans have become infected through direct contact with ailing birds, their feces or blood.
Indonesia has detected 49 cases of H5N1, 31 of those appearing since January, and ending in 37 fatalities.
BIRD FLU NEWS
How Did Seven Family Members Get Infected With Bird Flu?
19 May 2006
We still don't know how seven members of the same family in Indonesia became infected with the H5N1 bird flu virus strain. Six of them have died. It is vital to know whether some of them infected each other. If they did, this would mean that the virus might be changing.
The World Health Organization says that it is highly unlikely that H5N1 has mutated in this case. If it had, WHO believes more people from outside the family would have become infected.
The problem is that many days have passed and no one has managed to find any other source. If they had become infected by sick chickens or ducks, surely they would have been traced by now.
Henry Niman, Ph.D., President of Recombinomics, is calling for the release of the human H5N1 bird flu sequences from the dead family members which are held in the WHO database. He said the bimodal distribution of infection, starting with the index case who became ill on April 27, to family members in early May, indicates the possibility of human-to-human transmission. It is vital to know whether/how the H5N1 genome has changed.
Scientists fear that when the H5N1 bird flu virus strain mutates, it will gain the ability to transmit from human to human. At the moment it cannot do that easily. If it does manage to mutate in this way, we could be facing a serious flu pandemic. Nobody knows what the mutated virus will be like - it could be extremely lethal or relatively harmless.
Nowhere in the world so far, except in this case in Indonesia, have so many people of the same family become infected within a few days of each other.
Indonesia's neighbours are increasingly nervous at its inability to stop the bird flu spread. New cases of sick chickens have been reported in the eastern Papua province - which has alarmed Australia.
Over 200 million chickens live in people's backyards in Indonesia. This makes it especially hard to contain the bird flu spread and to really know how many sick chickens there are.
Indonesian authorities seem unable to cope with the task of implementing measures to control avian flu at the district level. Different regions of the country are doing what they can with very little supervision from central authorities.
WHO has urged Indonesian authorities to do more to raise public awareness.
Thailand and Vietnam have been praised for their effective efforts in containing the spread of avian influenza.
BIRD FLU NEWS:
Rate of bird flu deaths in Indonesia causes alarm
http://www.abc.net.au/am/content/2006/s1642346.htmSTORY
AM - Friday, 19 May , 2006 08:12:00
Reporter: Geoff Thompson
TONY EASTLEY: The World Health Organisation says human-to-human transmission of the bird-flu virus cannot be ruled out as the cause of an alarming cluster of human infections in Northern Sumatra.
20 people have now died of the virus in Indonesia this year.
While the Northern Sumatra cluster has not spread widely, bird flu experts are concerned by Indonesia's inability to contain it.
Geoff Thompson reports from Jakarta.
GEOFF THOMPSON: Five more bird flu deaths have been confirmed in Indonesia this week, meaning that more people are now dying of the virus in Indonesia than in any other country.
That stark truth prompted Indonesia's President, Susilo Bambang Yudhoyono, to appeal for international help yesterday, while addressing the UN's Food and Agriculture Organisation.
SUSILO BAMBANG YUDHOYNO: The stakes so high that the FAO must never cease reminding the international community to give full financial and technical support in the fight against avian influenza.
GEOFF THOMPSON: Particularly worrying is a cluster of seven mostly fatal human infections in Northern Sumatra.
Sari Setiogi is spokeswoman for the World Health Organisation in Indonesia.
SARI SETIOGI: It is true that what happened in North Sumatra is the largest cluster that we've ever had, both in Indonesia and globally. And every time there is a cluster case it will raise the suspicions that human-to-human transmission might have occurred.
However, as of yet, our investigation shows that there's no evidence of further spread of the virus beyond this family cluster.
GEOFF THOMPSON: A total of 31 people have now died from avian influenza in Indonesia. But what is frustrating health professionals is the fact that not a single source of infection has ever been confirmed for any of those deaths.
Yesterday, Indonesia's Agriculture Minister Anton Apriyantono reported that 10 pigs had tested positive for bird flu in the same village as the human cluster. Pigs are regarded as mixing vessels in which human and bird flu viruses can swap genes and potentially produce more easily transmissible mutations.
The pig test results need to be confirmed internationally. But an Australian bird flu expert who has worked in Indonesia for eight years, has an even greater concern.
Dr Andrew Jeremijenko says that some of the cluster patients were released back into the community before returning to hospital to die.
ANDREW JEREMIJENKO: This had been a test to see whether Indonesia could control a pandemic virus. Basically they just failed the test.
We now know it was a large cluster, there was possible human-to-human transmission and we have pigs testing positive.
Discharging a patient and then allowing him to come back a few days later when he was very, very sick and died is dangerous.
GEOFF THOMPSON: Bird flu has now also been confirmed in Papua, less than two hundred kilometres from the Australian mainland.
In Jakarta, this is Geoff Thompson for AM.
NVAX
NEXT GENERATION VACCINE PRODUCTION
Conference Call Earnings and guidance:
http://biz.yahoo.com/cc/2/68932.html
You can listen to "the minute marker" to review areas of interest!
NOVAVAX CONFERENCE SLIDE PRESENTATION:
http://library.corporate-ir.net/library/71/711/71178/items/198048/051506Q106.pdf
NVAX has many new products in their pipeline, as well as, the next generation vaccine production.
NVAX
bellwetherreport.com: BellwetherReport.com Issues Morning Alert for Novavax Inc.
May 19, 2006 (M2 PRESSWIRE via COMTEX) -- The Bellwether Report Takes Notice of Novavax Inc. (Nasdaq:NVAX) Novavax has a thing for women and their health. The company focuses primarily on prescription pharmaceuticals for women. It sells such products as pre-natal vitamins, oral contraceptives, and hormone replacement therapies. The company's topical creams include ESTRASORB and ANDROSORB, which deliver estrogen and testosterone through the skin. Novavax is also developing vaccines for the flu, HIV/AIDS, melanoma, and E-selectin tolerogen (secondary stroke prevention). In addition, the company is developing a vaccine for hepatitis E in collaboration with GlaxoSmithKline.
Shares were up 3% following the announcement that the Company will develop a novel medicine for women.
Novavax, Inc. today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).
Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II
clinical development.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory
milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from.....
I don't have the hang of this system and forget I have to )re-type) the stock name!
NVAX 4.49 + .06 High 4.64
Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
via COMTEX
May 19, 2006
Esprit Receives North American Marketing Rights
MALVERN, Pa., May 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Novavax, Inc. (Nasdaq: NVAX), today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).
Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II clinical development.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from this new agreement will be similar in scope to our prior license agreement with Esprit executed last year. Esprit will be responsible for all development costs and will lead clinical programs. Novavax will be responsible for manufacturing the product in its existing state-of-the-art facility located in Philadelphia.
"We are delighted with our second new partnership with Esprit and believe that we have the opportunity to develop and commercialize a best-in-class product for women with HSDD," said Ray Hage, Senior Vice President and Chief Operating Officer of Novavax. "John Spitznagel and his team at Esprit have a remarkable track record of launching successful new products and this product will be a strong addition to their portfolio."
Novavax first collaborated in a business relationship with Esprit late last year when Esprit licensed Novavax's estrogen therapy lotion, ESTRASORB(R), in North America.
"We are very excited about adding this key development program to our product pipeline," said John T. Spitznagel, Esprit's Chairman and Chief Executive Officer. "Novavax's unique technology delivers testosterone through the skin in a therapeutically effective and easy-to-use lotion. This product will be very appealing to women who suffer from this condition."
Novavax President and Chief Executive Dr. Rahul Singhvi, President said the agreement "further substantiates Novavax's capabilities in product development and validates the company's novel delivery system as an important technology." The U.S. Food and Drug Administration approved ESTRASORB(R), Novavax's first lotion therapy, in 2003.
"We are confident that our novel technology will continue to enable us to develop products that have the potential to improve patient health and quality of life as well as provide unique opportunities for companies like Esprit," Dr. Singhvi said.
About Novavax, Inc.
Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.
4.49 + .06 High 4.64
Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
via COMTEX
May 19, 2006
Esprit Receives North American Marketing Rights
MALVERN, Pa., May 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Novavax, Inc. (Nasdaq: NVAX), today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).
Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II clinical development.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from this new agreement will be similar in scope to our prior license agreement with Esprit executed last year. Esprit will be responsible for all development costs and will lead clinical programs. Novavax will be responsible for manufacturing the product in its existing state-of-the-art facility located in Philadelphia.
"We are delighted with our second new partnership with Esprit and believe that we have the opportunity to develop and commercialize a best-in-class product for women with HSDD," said Ray Hage, Senior Vice President and Chief Operating Officer of Novavax. "John Spitznagel and his team at Esprit have a remarkable track record of launching successful new products and this product will be a strong addition to their portfolio."
Novavax first collaborated in a business relationship with Esprit late last year when Esprit licensed Novavax's estrogen therapy lotion, ESTRASORB(R), in North America.
"We are very excited about adding this key development program to our product pipeline," said John T. Spitznagel, Esprit's Chairman and Chief Executive Officer. "Novavax's unique technology delivers testosterone through the skin in a therapeutically effective and easy-to-use lotion. This product will be very appealing to women who suffer from this condition."
Novavax President and Chief Executive Dr. Rahul Singhvi, President said the agreement "further substantiates Novavax's capabilities in product development and validates the company's novel delivery system as an important technology." The U.S. Food and Drug Administration approved ESTRASORB(R), Novavax's first lotion therapy, in 2003.
"We are confident that our novel technology will continue to enable us to develop products that have the potential to improve patient health and quality of life as well as provide unique opportunities for companies like Esprit," Dr. Singhvi said.
About Novavax, Inc.
Novavax is focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies. The company's technology platforms include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes(R), non-phospholipid vesicles and dendrimer technologies. The company is developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza strains using its VLP and Novasome adjuvant technologies. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) and Sterisomes(R), solvent and oil free emulsions for subcutaneous depot injection. The company has several products utilizing the MNP technology in various stages of development.
Do we have any TA experts here?
http://stockcharts.com/h-sc/ui?s=NVAX&p=D&yr=1&mn=0&dy=0&id=p87328075951&a=7...
SOIGF 3.70 + 92 NEWS
Press Release Source: Strata Oil & Gas Inc.
Strata Oil & Gas Announces 2-for-1 Forward Stock Split, Oil Sands Project Update
Friday May 12, 4:00 pm ET
CALGARY, AB--(MARKET WIRE)--May 12, 2006 -- Strata Oil and Gas (OTC BB:SOIGF.OB - News) is pleased to announce that its Board of Directors has approved a two-for-one forward stock split of its common stock to shareholders of record at the close of business on May 10th, 2006. Trading will begin on a split-adjusted basis on May 12th, 2006.
"This forward stock split is intended to enhance trading liquidity and broaden share ownership," said Manny Dhinsa, president of the company.
Strata's Peace River Oil Sands project is located directly to the southwest of Blackrock's Seal project. Blackrock was just purchased by Shell Canada in a friendly $2.4 billion cash offer.
Production in the Peace River Oil Sands area, which was once thought to require expensive thermal operations, has now been shown to be viable using cold production technology (CHOPS). Strata's scientific team has analyzed data from 21 existing wells that have been drilled on Strata's leases and an additional 165 wells in the area surrounding them.
The company has announced that it has engaged a Calgary-based petroleum exploration firm to assist in the planning, permitting and execution of a core hole drilling program on its 100%-owned Peace River Oil Sands project. The company's scientific team has recommended initiation of aggressive exploration on its wholly owned 26,000 acre oil sands package. The Peace River oil sands region of Alberta is estimated to contain more than 188 billion barrels of oil [Alberta Department of Energy, Cold Heavy Oil Production With Sand In The Canadian Heavy Oil Industry, Dr. Maurice Dusseault, March 2002].
"We believe the upside on our Peace River leases is substantial. Strata is uniquely positioned to provide exceptional shareholder returns in a rising oil market, and to provide greater exposure to petroleum prices by maximizing our in-place resource per common share," says Mr. Dhinsa. Strata Oil & Gas is a junior petroleum exploration company, with its head office located in Calgary, Alberta.
Strata Oil & Gas is a trademark of Strata Oil & Gas Inc. This announcement contains forward-looking statements which involve risks and uncertainties that include, among others, limited operating history, risks related to petroleum exploration, limited access to operating capital, and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. More information is included in Strata's filings with the Securities and Exchange Commission which may be accessed through the SEC's web site at http://www.sec.gov.
NVAX EARNINGS AND GUIDENCE MONDAY 5-15-06
The market is really in the dumpster today!
NVAX BUYING OPPORTUNITY
NOVAVAX INC (NasdaqNM:NVAX) Delayed quote data
Last Trade: 4.89
Trade Time: 12:53PM ET
Change: 0.20 (3.93%)
Prev Close: 5.09
Open: 5.09
Bid: 4.89 x 100
Ask: 4.89 x 400
1y Target Est: 6.50
Day's Range: 4.80 - 5.14
52wk Range: 0.70 - 8.39
Volume: 1,329,792
Avg Vol (3m): 6,400,820
Market Cap: 267.65M
P/E (ttm): N/A
EPS (ttm): -0.26
BUYING OPPORTUNITY!
NOVAVAX INC (NasdaqNM:NVAX) Delayed quote data
Last Trade: 4.89
Trade Time: 12:53PM ET
Change: 0.20 (3.93%)
Prev Close: 5.09
Open: 5.09
Bid: 4.89 x 100
Ask: 4.89 x 400
1y Target Est: 6.50
Day's Range: 4.80 - 5.14
52wk Range: 0.70 - 8.39
Volume: 1,329,792
Avg Vol (3m): 6,400,820
Market Cap: 267.65M
P/E (ttm): N/A
EPS (ttm): -0.26
3.30 + .52 1:07 pm
STRATA OIL & GAS INC (OTC BB:SOIGF.OB) Delayed quote data
Last Trade: 3.25
Trade Time: 12:51PM ET
Change: 0.47 (16.91%)
Prev Close: 2.78
Open: 3.25
Bid: 3.20 x 500
Ask: 3.25 x 500
1y Target Est: N/A
Day's Range: 2.50 - 4.40
52wk Range: N/A
Volume: 979,822
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A
IGII
Check it out!
IGII
http://www.otcbbcoverage.com/stocks/index.php?topic=30.0
IBSG International, Inc (IGII). is a holding company for three software subsidiaries: Intelligent Business Systems Group, Inc. (IBSG), a provider of turnkey digital service center software; Secure Blue, Inc., a Sarbanes-Oxley and security software solution provider and Intelligent Business Systems Development (IBSD), a software development, maintenance and data storage company.
DCEL 9.26 + 30
New Star Analyst Rankings for DOBSON COMM CP CL A
StarMine (Thu 11:03am)
• Dobson Buys Regional Wireless Provider
AP (Thu 8:21am)
• Dobson Communications to offer $250 million of senior notes
at Reuters (Thu 7:53am)
• Dobson subsidiary to buy Highland Cellular
at Reuters (Thu 7:42am)
STRATA OIL & GAS INC (OTC BB:SOIGF.OB) Delayed quote data
Last Trade: 5.48
Trade Time: 11:55AM ET
Change: 0.23 (4.38%)
Prev Close: 5.25
Open: 5.33
Bid: 5.42 x 500
Ask: 5.45 x 500
1y Target Est: N/A
Day's Range: 5.24 - 5.55
52wk Range: N/A
Volume: 161,639
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)
NVAX (Novavax)
A must read! http://www.novavax.com/
Press Release Source: Novavax, Inc.
Novavax Strengthens Vaccine Development Team with Two New Appointments
Thursday May 11, 10:47 am ET
* Dr. Jinyou Zhang Appointed as Senior Director of Bioprocess R & D
* Dr. Niranjan Kumar Appointed as Senior Director of Commercial Manufacturing
MALVERN, Pa., May 11 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) today announced the appointments of two senior biopharmaceutical scientists to augment the company's research and development and manufacturing capabilities. Dr. Jinyou Zhang, formerly senior investigator at Merck & Co., will serve as senior director of bioprocess R & D. Dr. Niranjan Kumar, who most recently was a deputy director at Sanofi Pasteur, has been named senior director of commercial manufacturing.
Related News Stories
· Novavax Head of Pharmaceutical Development to Present on Micellar Nanoparticle Technology at Particles 2006 Meeting - PR Newswire (Wed May 10)
· Novavax to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference - PR Newswire (Tue May 9)
· Novavax Announces Release Date of First Quarter 2006 Financial Results and Investor Conference Call - PR Newswire (Fri May 5)
· Novavax Earnings Call scheduled for Mon, May 15 - CCBN (Fri May 5)
More...
Thanks million for VPRO!
SENTO CORP (NasdaqSC:SNTO) Delayed quote data
Last Trade: 10.09
Trade Time: 11:45AM ET
Change: 0.90 (9.83%)
Prev Close: 9.19
Open: 9.89
Bid: 10.05 x 600
Ask: 10.07 x 5200
1y Target Est: N/A
Day's Range: 9.63 - 10.74
52wk Range: 2.20 - 10.75
Volume: 788,700
Avg Vol (3m): 49,609.7
Market Cap: 39.00M
P/E (ttm): N/A
EPS (ttm): -0.38
Div & Yield: N/A (N/A)
5-5-06
Tengasco, Inc. (TGC)
TGC quote Real-time quotes
1.90 +0.13 +7.34%
fyi Volume 656,000
5-8-06
Tengasco, Inc. (TGC)
TGC quote Real-time quotes
1.99 +0.06 +3.11%
fyi Volume 858,800
ON MY WATCH LIST:
5-5-06
Sento Corporation (SNTO)
SNTO quote Real-time quotes
8.85 +0.31 +3.63%
High 9.02
5-8-06
Sento Corporation (SNTO)
SNTO quote Real-time quotes
9.06 +0.11 +1.23%
Volume 3,645
On my watch list:
5-5-06
Strata Oil & Gas Inc (SOIGF)
SOIGF quote Real-time quotes
5.09 +0.09 +1.90%
5-8-06
Strata Oil & Gas Inc (SOIGF)
SOIGF quote Real-time quotes
5.20 +0.05 +0.97%